Mechanisms of cancer chemoprevention by soy isoflavone genistein

Cancer and Metastasis Reviews

Volumn 21, Issue 3-4, 2002, Pages 265-280

  Sarkar, Fazlul H ^a   Li, Yiwei ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Chemoprevention; Genistein; Soy isoflavone

Indexed keywords

ANDROGEN; ESTROGEN; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; PHYTOESTROGEN; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE; CELL SURVIVAL; CHEMOPROPHYLAXIS; DIETARY INTAKE; GENE ACTIVATION; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; METASTASIS; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; SIGNAL TRANSDUCTION; SOYBEAN;

ANIMALS; ANTICARCINOGENIC AGENTS; DIET; GENISTEIN; HUMANS; NEOPLASMS; SOYBEANS;

EID: 0036945663     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021210910821     Document Type: Review

References (136)

1. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC: Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol Biomarkers Prev 3: 85-98, 1994
2. Adlercreutz CH, Goldin BR, Gorbach SL, Hockerstedt KA, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT, Adlercreutz T: Soybean phytoestrogen intake and cancer risk. J Nutr 125: 757S-770S, 1995
3. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE: Dietary effects on breast-cancer risk in Singapore. Lancet 337: 1197-1200, 1991
4. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, Okada H: Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 54: 1093-1100, 1991
5. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS: Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study. J Natl Cancer Inst 90: 1637-1647, 1998
6. Jacobsen BK, Knutsen SF, Fraser GE: Does high soy milk intake reduce prostate cancer incidence? The Adventist health study (United States). Cancer Causes Control 9: 553-557, 1998
7. Adlercreutz H: Does fiber-rich food containing animal lignan precursors protect against both colon and breast cancer? An extension of the 'fiber hypothesis'. Gastroenterology 86: 761-764, 1984
8. Davis JN, Singh B, Bhuiyan M, Sarkar FH: Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32: 123-131, 1998
9. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH: Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 18: 3166-3172, 1999
10. Li Y, Bhuiyan M, Sarkar FH: Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol 15: 525-533, 1999
11. Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH: Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr Cancer 31: 184-191, 1998
12. Alhasan SA, Pietrasczkiwicz H, Alonso MD, Ensley J, Sarkar FH: Genistein-induced cell cycle arrest and apoptosis in a head and neck squamous cell carcinoma cell line. Nutr Cancer 34: 12-19, 1999
13. Upadhyay S, Neburi M, Chinni SR, Alhasan S, Miller F, Sarkar FH: Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21(WAF1). Clin Cancer Res 7: 1782-1789, 2001
14. Spinozzi F, Pagliacci MC, Migliorati G, Moraca R, Grignani F, Riccardi C, Nicoletti I: The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 18: 431-439, 1994
15. Constantinou A, Huberman E: Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action. Proc Soc Exp Biol Med 208: 109-115, 1995
16. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der BB, Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263, 1998
17. Adlercreutz H, Markkanen H, Watanabe S: Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342: 1209-1210, 1993
18. Knight DC, Eden JA: A review of the clinical effects of phytoestrogens. Obstet Gynecol 87: 897-904, 1996
19. Mills PK, Beeson WL, Phillips RL, Fraser GE: Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64: 598-604, 1989
20. Zava DT, Dollbaum CM, Blen M: Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 217: 369-378, 1998
21. Martin PM, Horwitz KB, Ryan DS, McGuire WL: Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 103: 1860-1867, 1978
22. Peterson G, Barnes S: Genistein inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 179: 661-667, 1991
23. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595, 1987
24. Hunter T: A thousand and one protein kinases. Cell 50: 823-829, 1987
25. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990
26. Okura A, Arakawa H, Oka H, Yoshinari T, Monden Y: Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 157: 183-189, 1988
27. Evans BA, Griffiths K, Morton MS: Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147: 295-302, 1995
28. Huang J, Nasr M, Kim Y, Matthews HR: Genistein inhibits protein histidine kinase. J Biol Chem 267: 15511-15515, 1992
29. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA: Antioxidant activity of phytoestrogenic isoflavones. Free Radic Res 26: 63-70, 1997
30. Zhou Y, Lee AS: Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J Natl Cancer Inst 90: 381-388, 1998
31. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE: Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J 15: 4682-4690, 1996
32. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274: 787-789, 1996
33. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998
34. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999
35. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R: Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Mol Pharmacol 51: 193-200, 1997
36. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L: Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 125: 790S-797S, 1995
37. Barnes S: Effect of genistein on in vitro and in vivo models of cancer. J Nutr 125: 777S-783S, 1995
38. Constantinou A, Kiguchi K, Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res 50: 2618-2624, 1990
39. Peterson G, Barnes S: Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 22: 335-345, 1993
40. Peterson G, Barnes S: Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ 7: 1345-1351, 1996
41. Buckley AR, Buckley DJ, Gout PW, Liang H, Rao YR Blake MJ: Inhibition by genistein of prolactin-induced Nb2 lymphoma cell mitogenesis. Mol Cell Endocrinol 98: 17-25, 1993
42. Schweigerer L, Christeleit K, Fleischmann G, Adlercreutz H, Wahala K, Hase T, Schwab M, Ludwig R, Fotsis T: Identification in human urine of a natural growth inhibitor for cells derived from solid paediatric tumours. Eur J Clin Invest 22: 260-264, 1992
43. Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Matsumoto K, Nishino H, Aoike A: Genistein arrests cell cycle progression at G2-M. Cancer Res 53: 1328-1331, 1993
44. Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I: Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 30A: 1675-1682, 1994
45. Casagrande F, Darbon JM: p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp Cell Res 258: 101-108, 2000
46. Kuzumaki T, Kobayashi T, Ishikawa K: Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem Biophys Res Commun 251: 291-295, 1998
47. Lian F, Li Y, Bhuiyan M, Sarkar FH: p53-independent apoptosis induced by genistein in lung cancer cells. Nutr Cancer 33: 125-131, 1999
48. Alhasan SA, Ensley JF, Sarkar FH: Genistein induced molecular changes in a squamous cell carcinoma of the head and neck cell line. Int J Oncol 16: 333-338, 2000
49. Chiarugi V, Magnelli L, Cinelli M, Basi G: Apoptosis and the cell cycle. Cell Mol Biol Res 40: 603-612, 1994
50. Huang P, Ballal K, Plunkett W: Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res 57: 3407-3414, 1997
51. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78: 539-542, 1994
52. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994
53. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809, 1995
54. Darmon AJ, Nicholson DW, Bleackley RC: Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 377: 446-448, 1995
55. Philpott NJ, Turner AJ, Scopes J, Westby M, Marsh JC, Gordon-Smith EC, Dalgleish AG, Gibson FM: The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques. Blood 87: 2244-2251, 1996
56. Park JR, Hockenbery DM: BCL-2, a novel regulator of apoptosis. J Cell Biochem 60: 12-17, 1996
57. Findley HW, Gu L, Yeager AM, Zhou M: Expression and regulation of Bcl-2, Bcl-x1, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89: 2986-2993, 1997
58. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T, Bredesen DE: Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262: 1274-1277, 1993
59. Salomons GS, Brady HJ, Verwijs-Janssen M, Van Den Berg JD, Hart AA, Van Den BH, Behrendt H, Hahlen K, Smets LA: The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int J Cancer 71: 959-965, 1997
60. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992
61. el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
62. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993
63. Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92: 8493-8497, 1995
64. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993
65. Shao ZM, Alpaugh ML, Fontana JA, Barsky SH: Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J Cell Biochem 69: 44-54, 1998
66. Wang TT, Sathyamoorthy N, Phang JM: Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 17: 271-275, 1996
67. Wang C, Kurzer MS: Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 28: 236-247, 1997
68. Papavassiliou AG: Transcription factors: Structure, function, and implication in malignant growth. Anticancer Res 15: 891-894, 1995
69. Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921-928, 1986
70. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S: Re1/NF-kappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev 9: 2723-2735, 1995
71. Thanos D, Maniatis T: NF-kappa B: A lesson in family values. Cell 80: 529-532, 1995
72. Ghosh G, van Duyne G, Ghosh S, Sigler PB: Structure of NF-kappa B p50 homodimer bound to a kappa B site. Nature 373: 303-310, 1995
73. Muller CW, Rey FA, Sodeoka M, Verdine GL, Harrison SC: Structure of the NF-kappa B p50 homodimer bound to DNA. Nature 373: 311-317, 1995
74. Muller CW, Harrison SC: The structure of the NF-kappa B p50:DNA-complex: A starting point for analyzing the Rel family. FEBS Lett 369: 113-117, 1995
75. Chen ZJ, Parent L, Maniatis T: Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 84: 853-862, 1996
76. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T: Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9: 1586-1597, 1995
77. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA: Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14: 2876-2883, 1995
78. Pahl HL, Baeuerle PA: Control of gene expression by proteolysis. Curr Opin Cell Biol 8: 340-347, 1996
79. Lenardo MJ, Baltimore D: NF-kappa B: A pleiotropic mediator of inducible and tissue-specific gene control. Cell 58: 227-229, 1989
80. Baldwin AS Jr.: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683, 1996
81. Beg AA, Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784, 1996
82. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr.: NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998
83. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376: 167-170, 1995
84. Davis JN, Kucuk O, Sarkar FH: Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr Cancer 35: 167-174, 1999
85. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U: Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267: 1485-1488, 1995
86. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M: A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388: 548-554, 1997
87. Jamaluddin M, Casola A, Garofalo RP, Han Y, Elliott T, Ogra PL, Brasier AR: The major component of IkappaBalpha proteolysis occurs independently of the proteasome pathway in respiratory syncytial virus-infected pulmonary epithelial cells. J Virol 72: 4849-4857, 1998
88. Zandi E, Chen Y, Karin M: Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: Discrimination between free and NF-kappaB-bound substrate. Science 281: 1360-1363, 1998
89. Karin M, Delhase M: The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 12: 85-98, 2000
90. Lee FS, Peters RT, Dang LC, Maniatis T: MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci USA 95: 9319-9324, 1998
91. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K: Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA 95: 3537-3542, 1998
92. Franke TF, Kaplan DR, Cantley LC: PI3K: Downstream AKTion blocks apoptosis. Cell 88: 435-437, 1997
93. Burgering BM, Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602, 1995
94. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81: 727-736, 1995
95. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996
96. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos GD, Glass DJ: Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741, 1999
97. Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90, 1999
98. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85, 1999
99. Sarkar, et al.: Our unpublished data
100. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM: Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 276: 13756-13761, 2001
101. Richter F, Huang HF, Li MT, Danielpour D, Wang SL, Irwin RJ Jr.: Retinoid and androgen regulation of cell growth, epidermal growth factor and retinoic acid receptors in normal and carcinoma rat prostate cells. Mol Cell Endocrinol 153: 29-38, 1999
102. Montgomery JS, Price DK, Figg WD: The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138-146, 2001
103. Kupelian P, Katcher J, Levin H, Zippe C, Klein E: Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48: 249-260, 1996
104. Luke MC, Coffey DS: Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl 15: 41-51, 1994
105. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD: Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 58: 139-146, 1996
106. Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH: Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol 16: 1091-1097, 2000
107. Sarkar, et al.: Our unpublished data
108. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JA, Carlquist M: Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18: 4608-4618, 1999
109. Lacroix H, Iglehart JD, Skinner MA, Kraus MH: Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145-151, 1989
110. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC: c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54: 3260-3266, 1994
111. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC: Liposome-mediated in vivo E1 A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 11: 1383-1388, 1995
112. Tan M, Yao J, Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205, 1997
113. Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecassis J: Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. Int J Cancer 48: 550-556, 1991
114. Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99-106, 1990
115. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327-336, 1991
116. Li Y, Bhuiyan M, Alhasan S, Senderowicz AM, Sarkar FH: Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin Cancer Res 6: 223-229, 2000
117. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L: Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr 125: 790S-797S, 1995
118. Roberts AB, Flanders KC, Heine UI, Jakowlew S, Kondaiah P, Kim SJ, Sporn MB: Transforming growth factor-beta: Multifunctional regulator of differentiation and development. Philos Trans R Soc Lond B Biol Sci 327: 145-154, 1990
119. Kim H, Peterson TG, Barnes S: Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 68: 1418S-1425S, 1998
120. Wei H, Wei L, Frenkel K, Bowen R, Barnes S: Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 20: 1-12, 1993
121. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD: Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 89: 123-134, 2000
122. van Rossen ME, Sluiter W, Bonthuis F, Jeekel H, Marquet RL, van Eijck CH: Scavenging of reactive oxygen species leads to diminished peritoneal tumor recurrence. Cancer Res 60: 5625-5629, 2000
123. Nagao N, Nakayama T, Etoh T, Saiki I, Miwa N: Tumor invasion is inhibited by phosphorylated ascorbate via enrichment of intracellular vitamin C and decreasing of oxidative stress. J Cancer Res Clin Oncol 126: 511-518, 2000
124. Nonaka Y, Iwagaki H, Kimura T, Fuchimoto S, Orita K: Effect of reactive oxygen intermediates on the in vitro invasive capacity of tumor cells and liver metastasis in mice. Int J Cancer 54: 983-986, 1993
125. Kameoka S, Leavitt P, Chang C, Kuo SM: Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary flavonoids. Cancer Lett 146: 161-167, 1999
126. Toledano MB, Leonard WJ: Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 88: 4328-4332, 1991
127. 2-mediated oxidative stress activates NF-kappaB in lens epithelial cells. Free Radic Biol Med 31: 651-658, 2001
128. Davis JN, Kucuk O, Djuric Z, Sarkar FH: Soy isoflavone supplementation in healthy men prevents NF-kappaB activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 30: 1293-1302, 2001
129. Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS, Ewing LL: Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 43: 557-564, 1992
130. Onozawa M, Kawamori T, Baba M, Fukuda K, Toda T, Sato H, Ohtani M, Akaza H, Sugimura T, Wakabayashi K: Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cancer Res 90: 393-398, 1999
131. Landstrom M, Zhang JX, Hallmans G, Aman P, Bergh A, Damber JE, Mazur W, Wahala K, Adlercreutz H: Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 36: 151-161, 1998
132. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK: Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129: 1628-1635, 1999
133. Li D, Yee JA, McGuire MH, Murphy PA, Yan L: Soybean isoflavones reduce experimental metastasis in mice. J Nutr 129: 1075-1078, 1999
134. Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MJ, Barnes S: Genistein suppresses mammary cancer in rats. Carcinogenesis 16: 2833-2840, 1995
135. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, Burkhardt A, Bolen J, Myers DE: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267: 886-891, 1995
136. Sarkar, et al.: Our unpublished data